DOCSLIB.ORG

ATC Code Title

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ATC Code Title ATC Code Title A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AA CARIES PROPHYLACTIC AGENTS A01AA01 SODIUM FLUORIDE A01AA02 SODIUM MONOFLUOROPHOSPHATE A01AA03 OLAFLUR A01AA04 STANNOUS FLUORIDE A01AA30 COMBINATIONS A01AA51 SODIUM FLUORIDE, COMBINATIONS A01AB ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL TREATMENT A01AB02 HYDROGEN PEROXIDE A01AB03 CHLORHEXIDINE A01AB04 AMPHOTERICIN B A01AB05 POLYNOXYLIN A01AB06 DOMIPHEN A01AB07 OXYQUINOLINE A01AB08 NEOMYCIN A01AB09 MICONAZOLE A01AB10 NATAMYCIN A01AB11 VARIOUS A01AB12 HEXETIDINE A01AB13 TETRACYCLINE A01AB14 BENZOXONIUM CHLORIDE A01AB15 TIBEZONIUM IODIDE A01AB16 MEPARTRICIN A01AB17 METRONIDAZOLE A01AB18 CLOTRIMAZOLE A01AB19 SODIUM PERBORATE A01AB21 CHLORTETRACYCLINE A01AB22 DOXYCYCLINE A01AB23 MINOCYCLINE A01AC CORTICOSTEROIDS FOR LOCAL ORAL TREATMENT A01AC01 TRIAMCINOLONE A01AC02 DEXAMETHASONE A01AC03 HYDROCORTISONE A01AC54 PREDNISOLONE, COMBINATIONS A01AD OTHER AGENTS FOR LOCAL ORAL TREATMENT A01AD01 EPINEPHRINE A01AD02 BENZYDAMINE A01AD05 ACETYLSALICYLIC ACID A01AD06 ADRENALONE A01AD07 AMLEXANOX A01AD08 BECAPLERMIN A01AD11 VARIOUS A02 DRUGS FOR ACID RELATED DISORDERS A02A ANTACIDS A02AA MAGNESIUM COMPOUNDS A02AA01 MAGNESIUM CARBONATE A02AA02 MAGNESIUM OXIDE A02AA03 MAGNESIUM PEROXIDE A02AA04 MAGNESIUM HYDROXIDE A02AA05 MAGNESIUM SILICATE A02AA10 COMBINATIONS A02AB ALUMINIUM COMPOUNDS A02AB01 ALUMINIUM HYDROXIDE A02AB02 ALGELDRATE A02AB03 ALUMINIUM PHOSPHATE A02AB04 DIHYDROXIALUMINI SODIUM CARBONATE A02AB05 ALUMINIUM ACETOACETATE A02AB06 ALOGLUTAMOL A02AB07 ALUMINIUM GLYCINATE A02AB10 COMBINATIONS A02AC CALCIUM COMPOUNDS A02AC01 CALCIUM CARBONATE A02AC02 CALCIUM SILICATE A02AC10 COMBINATIONS A02AD COMBINATIONS AND COMPLEXES OF ALUMINIUM, CALCIUM AND MAGNESIUM COMPOUNDS A02AD01 ORDINARY SALT COMBINATIONS A02AD02 MAGALDRATE A02AD03 ALMAGATE A02AD04 HYDROTALCITE A02AD05 ALMASILATE A02AF ANTACIDS WITH ANTIFLATULENTS A02AF01 MAGALDRATE AND ANTIFLATULENTS A02AF02 ORDINARY SALT COMBINATIONS AND ANTIFLATULENTS A02AG ANTACIDS WITH ANTISPASMODICS A02AH ANTACIDS WITH SODIUM BICARBONATE A02AX ANTACIDS, OTHER COMBINATIONS A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-RECEPTOR ANTAGONISTS A02BA01 CIMETIDINE A02BA02 RANITIDINE A02BA03 FAMOTIDINE A02BA04 NIZATIDINE A02BA05 NIPEROTIDINE A02BA06 ROXATIDINE A02BA07 RANITIDINE BISMUTH CITRATE A02BA08 LAFUTIDINE A02BA51 CIMETIDINE, COMBINATIONS A02BA53 FAMOTIDINE, COMBINATIONS A02BB PROSTAGLANDINS A02BB01 MISOPROSTOL A02BB02 ENPROSTIL A02BC PROTON PUMP INHIBITORS A02BC01 OMEPRAZOLE A02BC02 PANTOPRAZOLE A02BC03 LANSOPRAZOLE A02BC04 RABEPRAZOLE A02BC05 ESOMEPRAZOLE A02BC06 DEXLANSOPRAZOLE A02BD COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLORI A02BD01 OMEPRAZOLE, AMOXICILLIN AND METRONIDAZOLE A02BD02 LANSOPRAZOLE, TETRACYCLINE AND METRONIDAZOLE A02BD03 LANSOPRAZOLE, AMOXICILLIN AND METRONIDAZOLE A02BD04 PANTOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN A02BD05 OMEPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN A02BD06 ESOMEPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN A02BD07 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN A02BD08 BISMUTH SUBCITRATE, TETRACYCLINE AND METRONIDAZOLE A02BX OTHER DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BX01 CARBENOXOLONE A02BX02 SUCRALFATE A02BX03 PIRENZEPINE A02BX04 METHIOSULFONIUM CHLORIDE A02BX05 BISMUTH SUBCITRATE A02BX06 PROGLUMIDE A02BX07 GEFARNATE A02BX08 SULGLICOTIDE A02BX09 ACETOXOLONE A02BX10 ZOLIMIDINE A02BX11 TROXIPIDE A02BX12 BISMUTH SUBNITRATE A02BX13 ALGINIC ACID A02BX51 CARBENOXOLONE, COMBINATIONS EXCL. PSYCHOLEPTICS A02BX71 CARBENOXOLONE, COMBINATIONS WITH PSYCHOLEPTICS A02BX77 GEFARNATE, COMBINATIONS WITH PSYCHOLEPTICS A02X OTHER DRUGS FOR ACID RELATED DISORDERS A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS A03AA SYNTHETIC ANTICHOLINERGICS, ESTERS WITH TERTIARY AMINO GROUP A03AA01 OXYPHENCYCLIMINE A03AA03 CAMYLOFIN A03AA04 MEBEVERINE A03AA05 TRIMEBUTINE A03AA06 ROCIVERINE A03AA07 DICYCLOVERINE A03AA08 DIHEXYVERINE A03AA09 DIFEMERINE A03AA30 PIPERIDOLATE A03AB SYNTHETIC ANTICHOLINERGICS, QUATERNARY AMMONIUM COMPOUNDS A03AB01 BENZILONE A03AB02 GLYCOPYRRONIUM BROMIDE A03AB03 OXYPHENONIUM A03AB04 PENTHIENATE A03AB05 PROPANTHELINE A03AB06 OTILONIUM BROMIDE A03AB07 METHANTHELINE A03AB08 TRIDIHEXETHYL A03AB09 ISOPROPAMIDE A03AB10 HEXOCYCLIUM A03AB11 POLDINE A03AB12 MEPENZOLATE A03AB13 BEVONIUM A03AB14 PIPENZOLATE A03AB15 DIPHEMANIL A03AB16 (2-BENZHYDRYLOXYETHYL)DIETHYL-METHYLAMMONIUM IODIDE A03AB17 TIEMONIUM IODIDE A03AB18 PRIFINIUM BROMIDE A03AB19 TIMEPIDIUM BROMIDE A03AB21 FENPIVERINIUM A03AB53 OXYPHENONIUM, COMBINATIONS A03AC SYNTHETIC ANTISPASMODICS, AMIDES WITH TERTIARY AMINES A03AC02 DIMETHYLAMINOPROPIONYLPHENOTHIAZINE A03AC04 NICOFETAMIDE A03AC05 TIROPRAMIDE A03AD PAPAVERINE AND DERIVATIVES A03AD01 PAPAVERINE A03AD02 DROTAVERINE A03AD30 MOXAVERINE A03AE SEROTONIN RECEPTOR ANTAGONISTS A03AE01 ALOSETRON A03AE03 CILANSETRON A03AX OTHER DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS A03AX01 FENPIPRANE A03AX02 DIISOPROMINE A03AX03 CHLORBENZOXAMINE A03AX04 PINAVERIUM A03AX05 FENOVERINE A03AX06 IDANPRAMINE A03AX07 PROXAZOLE A03AX08 ALVERINE A03AX09 TREPIBUTONE A03AX10 ISOMETHEPTENE A03AX11 CAROVERINE A03AX12 PHLOROGLUCINOL A03AX13 SILICONES A03AX30 TRIMETHYLDIPHENYLPROPYLAMINE A03AX58 ALVERINE, COMBINATIONS A03B BELLADONNA AND DERIVATIVES, PLAIN A03BA BELLADONNA ALKALOIDS, TERTIARY AMINES A03BA01 ATROPINE A03BA03 HYOSCYAMINE A03BA04 BELLADONNA TOTAL ALKALOIDS A03BB BELLADONNA ALKALOIDS, SEMISYNTHETIC, QUATERNARY AMMONIUM COMPOUNDS A03BB01 BUTYLSCOPOLAMINE A03BB02 METHYLATROPINE A03BB03 METHYLSCOPOLAMINE A03BB04 FENTONIUM A03BB05 CIMETROPIUM BROMIDE A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03CA SYNTHETIC ANTICHOLINERGIC AGENTS IN COMBINATION WITH PSYCHOLEPTICS A03CA01 ISOPROPAMIDE AND PSYCHOLEPTICS A03CA02 CLIDINIUM AND PSYCHOLEPTICS A03CA03 OXYPHENCYCLIMINE AND PSYCHOLEPTICS A03CA04 OTILONIUM BROMIDE AND PSYCHOLEPTICS A03CA05 GLYCOPYRRONIUM BROMIDE AND PSYCHOLEPTICS A03CA06 BEVONIUM AND PSYCHOLEPTICS A03CA07 AMBUTONIUM AND PSYCHOLEPTICS A03CA08 DIPHEMANIL AND PSYCHOLEPTICS A03CA30 EMEPRONIUM AND PSYCHOLEPTICS A03CA34 PROPANTHELINE AND PSYCHOLEPTICS A03CB BELLADONNA AND DERIVATIVES IN COMBINATION WITH PSYCHOLEPTICS A03CB01 METHYLSCOPOLAMINE AND PSYCHOLEPTICS A03CB02 BELLADONNA TOTAL ALKALOIDS AND PSYCHOLEPTICS A03CB03 ATROPINE AND PSYCHOLEPTICS A03CB04 METHYLHOMATROPINE AND PSYCHOLEPTICS A03CB31 HYOSCYAMINE AND PSYCHOLEPTICS A03CC OTHER ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03D ANTISPASMODICS IN COMBINATION WITH ANALGESICS A03DA SYNTHETIC ANTICHOLINERGIC AGENTS IN COMBINATION WITH ANALGESICS A03DA01 TROPENZILONE AND ANALGESICS A03DA02 PITOFENONE AND ANALGESICS A03DA03 BEVONIUM AND ANALGESICS A03DA04 CICLONIUM AND ANALGESICS A03DA05 CAMYLOFIN AND ANALGESICS A03DA06 TROSPIUM AND ANALGESICS A03DA07 TIEMONIUM IODIDE AND ANALGESICS A03DB BELLADONNA AND DERIVATIVES IN COMBINATION WITH ANALGESICS A03DB04 BUTYLSCOPOLAMINE AND ANALGESICS A03DC OTHER ANTISPASMODICS IN COMBINATION WITH ANALGESICS A03E ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS A03EA ANTISPASMODICS, PSYCHOLEPTICS AND ANALGESICS IN COMBINATION A03ED ANTISPASMODICS IN COMBINATION WITH OTHER DRUGS A03F PROPULSIVES A03FA PROPULSIVES A03FA01 METOCLOPRAMIDE A03FA02 CISAPRIDE A03FA03 DOMPERIDONE A03FA04 BROMOPRIDE A03FA05 ALIZAPRIDE A03FA06 CLEBOPRIDE A04 ANTIEMETICS AND ANTINAUSEANTS A04A ANTIEMETICS AND ANTINAUSEANTS A04AA SEROTONIN (5HT3) ANTAGONISTS A04AA01 ONDANSETRON A04AA02 GRANISETRON A04AA03 TROPISETRON A04AA04 DOLASETRON A04AA05 PALONOSETRON A04AD OTHER ANTIEMETICS A04AD01 SCOPOLAMINE A04AD02 CERIUM OXALATE A04AD04 CHLOROBUTANOL A04AD05 METOPIMAZINE A04AD10 DRONABINOL A04AD11 NABILONE A04AD12 APREPITANT A04AD13 CASOPITANT A04AD51 SCOPOLAMINE, COMBINATIONS A04AD54 CHLOROBUTANOL, COMBINATIONS A05 BILE AND LIVER THERAPY A05A BILE THERAPY A05AA BILE ACID PREPARATIONS A05AA01 CHENODEOXYCHOLIC ACID A05AA02 URSODEOXYCHOLIC ACID A05AA03 CHOLIC ACID A05AB PREPARATIONS FOR BILIARY TRACT THERAPY A05AB01 NICOTINYL METHYLAMIDE A05AX OTHER DRUGS FOR BILE THERAPY A05AX01 PIPROZOLIN A05AX02 HYMECROMONE A05AX03 CYCLOBUTYROL A05B LIVER THERAPY, LIPOTROPICS A05BA LIVER THERAPY A05BA01 ARGININE GLUTAMATE A05BA03 SILYMARIN A05BA04 CITIOLONE A05BA05 EPOMEDIOL A05BA06 ORNITHINE OXOGLURATE A05BA07 TIDIACIC ARGININE A05BA08 GLYCYRRHIZIC ACID A05C DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION A06 DRUGS FOR CONSTIPATION A06A DRUGS FOR CONSTIPATION A06AA SOFTENERS, EMOLLIENTS A06AA01 LIQUID PARAFFIN A06AA02 DOCUSATE SODIUM A06AA51 LIQUID PARAFFIN, COMBINATIONS A06AB CONTACT LAXATIVES A06AB01 OXYPHENISATINE A06AB02 BISACODYL A06AB03 DANTRON A06AB04 PHENOLPHTHALEIN A06AB05 CASTOR OIL A06AB06 SENNA GLYCOSIDES A06AB07 CASCARA A06AB08 SODIUM PICOSULFATE A06AB09 BISOXATIN A06AB20 CONTACT LAXATIVES IN COMBINATION A06AB30 CONTACT LAXATIVES IN COMBINATION WITH BELLADONNA ALKALOIDS A06AB52 BISACODYL, COMBINATIONS A06AB53 DANTRON, COMBINATIONS A06AB56 SENNA GLYCOSIDES, COMBINATIONS A06AB57 CASCARA, COMBINATIONS A06AB58 SODIUM PICOSULFATE, COMBINATIONS A06AC BULK-FORMING LAXATIVES A06AC01 ISPAGHULA (PSYLLA SEEDS) A06AC02 ETHULOSE A06AC03 STERCULIA A06AC05 LINSEED A06AC06 METHYLCELLULOSE A06AC07 TRITICUM (WHEAT FIBRE) A06AC08 POLYCARBOPHIL CALCIUM A06AC51 ISPAGHULA, COMBINATIONS A06AC53 STERCULIA, COMBINATIONS A06AC55 LINSEED, COMBINATIONS A06AD OSMOTICALLY ACTING LAXATIVES A06AD01 MAGNESIUM CARBONATE A06AD02 MAGNESIUM OXIDE A06AD03 MAGNESIUM PEROXIDE A06AD04 MAGNESIUM
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Clinical Significance of Small Molecule Metabolites in the Blood of Patients
    www.nature.com/scientificreports OPEN Clinical signifcance of small molecule metabolites in the blood of patients with diferent types of liver injury Hui Li1,2,5, Yan Wang1,5, Shizhao Ma1,3, Chaoqun Zhang1,4, Hua Liu2 & Dianxing Sun1,4* To understand the characteristic of changes of serum metabolites between healthy people and patients with hepatitis B virus (HBV) infection at diferent stages of disease, and to provide reference metabolomics information for clinical diagnosis of liver disease patients. 255 patients with diferent stages of HBV infection were selected. 3 mL blood was collected from each patient in the morning to detect diferences in serum lysophosphatidylcholine, acetyl-l-carnitine, oleic acid amide, and glycocholic acid concentrations by UFLC-IT-TOF/MS. The diagnostic values of four metabolic substances were evaluated by receiver operating characteristic (ROC) curve. The results showed that the optimal cut-of value of oleic acid amide concentration of the liver cirrhosis and HCC groups was 23.6 mg/L, with a diagnostic sensitivity of 88.9% and specifcity of 70.6%. The diagnostic efcacies of the three substances were similar in the hepatitis and HCC groups, with an optimal cut-of value of 2.04 mg/L, and a diagnostic sensitivity and specifcity of 100% and 47.2%, respectively. The optimal cut-of value of lecithin of the HBV-carrier and HCC groups was 132.85 mg/L, with a diagnostic sensitivity and specifcity of 88.9% and 66.7%, respectively. The optimal cut-of value of oleic acid amide of the healthy and HCC groups was 129.03 mg/L, with a diagnostic sensitivity and specifcity of 88.4% and 83.3%, respectively.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Allergies Your Amerigroup Community Care Patients May Experience a Pharmacy Claim Rejection When Prescribed Nonpreferred Products
    Provider update Hot Tip: Allergies Your Amerigroup Community Care patients may experience a pharmacy claim rejection when prescribed nonpreferred products. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Utilization Management edits may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Amerigroup provider website. The PDL is subject to change quarterly. Therapeutic class Preferred products Nonpreferred products Oral • Fexofenadine (generic Allegra) • Cetirizine (generic Zyrtec) antihistamines1 • Fexofenadine/ pseudoephedrine • Cetirizine/pseudoephedrine (generic Allegra-D) (generic Zyrtec D) • Loratadine (generic Claritin) • Zyrtec (cetirizine) • Loratadine/pseudoepherine • Zyrtec D (cetirizine/ (generic Claritin D) pseudoephedrine) • Clarinex (desloratadine) • Desloratadine (generic Clarinex) • Alegra (fexofenadine) • Allegra D (fexofenadine/ pseudoephedrine) • Levocetirizine (generic Xyzal) • Xyzal (levocetirizine) • Claritin (loratadine) • Claritin D (loratadine/ pseudoephedrine) Nasal steroids2 • OTC budesonide nasal spray • Flonase Sensimist (fluticasone (generic Rhinocort) furoate) • OTC Rhinocort Allergy • Flonase (fluticasone propionate) (budesonide) • Rx fluticasone propionate (generic • OTC fluticasone propionate Rx Flonase) (generic Flonase) • Mometasone furoate (generic • OTC triamcinolone acetonide Nasonex) (generic Nasacort) • Nasacort (triamcinolone acetonide) • Nasonex (mometasone furoate) • Omnaris
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Regulatory News
    WHO Drug Information Vol. 28, No. 4, 2014 Regulatory news Ebola curative – transfusions of whole blood or blood plasma from recovered patients Update on treatments and vaccines have been scheduled to be conducted in Liberia, in line with WHO technical The Ebola crisis has prompted an guidelines (4). unprecedented cooperation between regulators In September the European Medicines to support WHO and to advise on possible Agency (EMA) established an expert pathways for the development, evaluation and group to review available information approval of medicines to fight Ebola. Progress on Ebola experimental treatments – towards provision of treatments and vaccines is excluding convalescent therapies – and summarized below. invited developers to submit their data (5). In August 2014, a WHO-convened panel Vaccines had agreed unanimously that is ethically On 29–30 September, 70 experts acceptable to use of experimental attended a WHO-convened consultation medicines and vaccines under the on Ebola vaccines. They took stock of the exceptional circumstances of the Ebola many ongoing efforts to rapidly evaluate epidemic (1). In early September, WHO the safety and efficacy of Ebola vaccines convened a consultation on potential for deployment as soon as possible to Ebola therapies and vaccines (2). The critical frontline workers and ultimately to importance of supportive care and populations at risk in mass vaccination community response was stressed in this campaigns. Two candidate vaccines have and subsequent discussions. clinical-grade vials available for safety trials. (6) Treatments In October, WHO convened industry In September, more than 200 experts leaders and key partners to discuss trials from around the world met at WHO and production of Ebola vaccine (7).
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]